COMBINATION THERAPIES FOR TREATMENT OF HER2 CANCER

Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant br...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	JOO Stephanie Royer, SONG Kyung Wha, WARBURTON Simon Peter, DEY Anwesha, SCHUTZMAN Jennifer Lee, THANOPOULOU Eirini, SONG Chunyan
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab). Se proporcionan tratamientos conjuntos que comprenden inavolisib (también denominado GDC-0077) y otros tratamientos dirigidos a HER2 (por ejemplo, pertuzumab y trastuzumab) para el tratamiento de tipos de cáncer positivos para HER2; y métodos para tratar tipos de cáncer positivos para HER2 (HER2+) en un paciente (preferentemente un paciente con cáncer de mama con PIK3CA mutante) que comprende administrar una cantidad terapéuticamente eficaz de inavolisib y un tratamiento dirigido a HER2 (por ejemplo, trastuzumab, pertuzumab, o una combinación de trastuzumab y pertuzumab).